“The premium is not out of whack when you look at the scarcity value of this technology and the appetite for biotech companies right now. It’s a small deal in size but a large deal in terms of the potential scope they gain with this science.”

Reuters talks to journalistic favourite “a source familiar with the deal” about the potential $2.4 billion purchase of Medarex by Bristol-Myers Squibb.

“Procter & Gamble Co. is getting closer to a possible sale of its prescription-drug business, and several parties … are engaged in later-stage discussions, according to people familiar with the matter. The unit could fetch about $3 billion, these people say.”

The Wall Street Journal looks at another possible buy out.

“It is not impossible to build a human brain and we can do it in 10 years.”

Henry Markram, director of the Blue Brain Project, addresses the TED Global conference in Oxford (BBC).